A common Japanese vernacular category. A complicated, contested, multi-component clinical reality. The mismatch between the vernacular framing — “a woman who does not feel” — and the contemporary clinical understanding of the conditions underlying the category is one of the more substantial vocabulary-clinical-mismatch instances in contemporary Japanese sexual medicine.

Fukanshō (Japanese: 不感症, fukanshō, “non-sensation condition”; English working translations: anorgasmia, female sexual dysfunction (FSD), the deprecated frigidity) is a Japanese vernacular term covering the broad clinical territory in which a woman’s body or subjective experience does not respond to sexual stimulation as expected. The term is not a single diagnostic category in the contemporary clinical-diagnostic frameworks (DSM-5, ICD-11); the English-language clinical vocabulary divides the territory across multiple specific diagnoses.

This entry covers the clinical decomposition of the broader Japanese vernacular term, the recognised biological-psychological-relational causes, the cultural framing of the term, and the contemporary treatment approaches.

Distinction in vocabulary

The Japanese fukanshō is a broad vernacular category. In contemporary Japanese clinical and educational writing, it is widely avoided in favour of the more specific clinical-diagnostic vocabulary, because the broad term carries pejorative implication (“a woman who does not feel”, with the implicit framing of personal defect) that the underlying clinical conditions do not warrant.

The English-language clinical vocabulary distributes the territory across multiple specific diagnoses. Anorgasmia (or orgasmic dysfunction) names specifically the inability to reach orgasm despite adequate stimulation. Hypoactive sexual desire disorder (HSDD) names specifically the persistent absence or marked decline of sexual interest. Female sexual interest/arousal disorder (FSIAD, the DSM-5 consolidation introduced in 2013) covers the combined category of interest-and-arousal difficulty.

The older English-language frigidity term is now deprecated in clinical writing for the same reasons that fukanshō is increasingly avoided in Japanese clinical writing: the term carries personal-defect framing that the underlying conditions do not warrant.

Clinical decomposition (FSD)

The contemporary clinical vocabulary divides the broader female sexual-dysfunction category into four main components:

Female sexual interest / arousal disorder (FSIAD)

Persistent inadequate interest in sexual activity, and / or inadequate subjective and / or physical arousal in response to sexual stimulation. The DSM-5 (2013) consolidated the previously-separate desire-disorder and arousal-disorder categories into the combined FSIAD diagnosis, reflecting the substantial empirical overlap between the two. ICD-11 (2022) retains the separation between hypoactive sexual desire dysfunction and female sexual arousal dysfunction as separate diagnostic categories.

Orgasmic dysfunction

Inability to reach orgasm in response to sexual stimulation, or substantial delay or reduction in orgasm response. The detailed coverage is in the dedicated orgasm-disorder entry.

Sexual-pain-related dysfunction

Pain experienced during or in anticipation of sexual activity, disrupting interest and arousal. Includes dyspareunia (pain during intercourse) and vaginismus (involuntary pelvic-floor muscle contraction).

Hypoactive sexual desire disorder (HSDD)

Persistent and marked decline in sexual interest and fantasy. The DSM-5 absorbed HSDD into FSIAD; ICD-11 retains it as a separate category. The conceptual distinction between general low-libido and clinical disorder remains a recurring topic in the contemporary literature.

Causes

The contemporary clinical understanding treats the causes of conditions in the fukanshō / FSD category as multifactorial, with biological, psychological, relational, and pharmacological dimensions all operating in most cases.

Hormonal factors

Testosterone and oestrogen decline both affect sexual interest, arousal, and orgasmic response. Menopause, post-partum / lactation periods, and post-oophorectomy states each present substantial hormone-shift dynamics that contribute to FSD presentations. Testosterone is produced in women through both adrenal and ovarian pathways, and substantial decline in either pathway can produce notable libido decline; the dynamics differ between pre- and post-menopausal women.

Pharmacological factors

SSRI-class antidepressants are widely associated with sexual side-effects including genital anaesthesia, orgasm delay, libido reduction, and overall reduced sexual response. The side-effect profile is sufficiently common that medication-induced FSD presentations are a regularly-encountered clinical population. Anti-epileptics, antipsychotics, and beta-blocker antihypertensives have parallel sexual-side-effect profiles, with the specific drug and dose driving the magnitude of effect.

Psychological factors

Depression, anxiety, post-traumatic stress disorder, sexual-trauma history, body-image concern, and sex-related shame-and-guilt all contribute. Internalised messages (“I should not feel pleasure”, “wanting pleasure is shameful”) frequently operate in the background, particularly in cultural contexts where sex-affirmative messaging in adolescent and adult education has been limited.

Relational factors

Partner communication failure, relationship-satisfaction decline, sexual-compatibility issues, and unaddressed relationship conflict all contribute substantially. Clinical practice in contemporary sex-medicine consistently emphasises the relational dimension as one of the most-frequently-underdiagnosed contributing factors.

The vocabulary problem

The vernacular framing of fukanshō and the deprecated frigidity terms carry the implicit framing that the affected woman is the problem — that the absence of expected response is a personal deficit. The contemporary clinical understanding rejects this framing on multiple grounds.

First, women’s sexual response is, on average, more stimulus-context-and-relational-context dependent than men’s sexual response, with substantially greater individual-variation in what constitutes adequate stimulation. The condition of “not responding to inadequate stimulation in an inadequate context” is, in this framework, normal female sexual response rather than dysfunction.

Second, the diagnosis of “fukanshō” is frequently made from a partner perspective (“my partner does not respond to my approach”) rather than from the affected person’s own experience. The mismatch between partner-framed and self-framed evaluations of the same situation has produced substantial mis-attribution in clinical practice, with what is fundamentally a couple-level communication-and-technique issue framed as a unilateral defect of one partner.

Third, the diagnosis frequently functions to displace the partner’s responsibility for the relational and technical aspects of the sexual encounter onto the affected woman, with the diagnostic framing supporting the displacement. The contemporary clinical and sex-therapy practice consistently flags this displacement pattern and reframes the situation in couple-level terms.

Emily Nagoski’s Come as You Are (2015), among the most widely-cited contemporary popular-press accounts of female sexual response, develops the “dual-control-model” framework — sexual response as the dynamic interplay of accelerator (sexually-relevant-stimuli) and brake (sexually-inhibiting-context) — as an alternative to the personal-defect framing.

Treatment

Contemporary treatment is multimodal and tailored to the underlying mix of causes.

For hormonal contributors, local oestrogen therapy is effective in addressing the post-menopausal urogenital-atrophy component (vaginal dryness, atrophic vaginitis, and related symptoms). Systemic low-dose testosterone supplementation for HSDD has empirical support in international literature but is not currently approved for this indication in Japan, requiring off-label or compounded prescribing where used.

For pharmacological contributors, medication adjustment (alternative SSRI, dose modification, addition of compensatory medication such as bupropion) addresses the side-effect-induced component. The decision balance between depression-treatment and sexual-side-effect is individual to the affected person.

For psychological contributors, cognitive-behavioural therapy, mindfulness-based sex therapy, and sex-therapy with a trained sex therapist all have substantial empirical support. Self-pleasure (masturbation) exploration to map the individual’s own sexual-response patterns is a recurring educational-and-therapeutic component.

For relational contributors, couples-therapy, sex-therapy, and communication-and-technique-coaching are central. The framing of the issue as a couple-level concern rather than as a unilateral defect of one partner is itself a therapeutic intervention in many cases.

Cultural context

The substantial gap between the clinical understanding of FSD and the vernacular framing of fukanshō is one of the recognised problems in Japanese clinical sex-medicine. Lower public-awareness of sex-as-clinical-issue, more-restricted school-and-public sex-education, and lower routine sexual-health-discussion in clinical contexts all contribute. The 2010s-onward growth of patient-support organisations, popular-press writing on female sexual health, and clinical-and-educational outreach have begun to close the gap, but with substantial work remaining.

Related Terms

• Libido
• Orgasm disorder
• Sex hormones
• Vaginismus (chitsu-keiren)
• Dyspareunia
• Erectile dysfunction (bokki-shougai) — male-counterpart category
• Couple sexuality